Company intelligence / Profile preview
Aclaris Therapeutics, Inc.
Wayne, Pennsylvania, United Statesaclaristx.com ↗
- Ownership
- Public · ACRS
- Employees
- ~200
- Development stage
- Other
01
Overview
Aclaris is advancing multiple clinical programs including bosakitug (ATI-045) in atopic dermatitis with Phase 2b trial enrollment expected in first half of 2025, ATI-2138 with Phase 2a results expected in first half of 2025, and recently received FDA IND clearance for ATI-052 with Phase 1a/1b trial expected to begin in Q2 2025[7][8]
- Therapeutic areas
- ImmunologyDermatologyPulmonology
- Modalities
- Small moleculesmonoclonal antibodiesbispecific antibodieskinase inhibitors
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ)Biosion, Inc.
04
Financials
- Market cap
- $531.4M
- Total revenue
- $7.8M
- Enterprise value
- $306.4M
Beyond the preview
Go deeper on Aclaris Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aclaris Therapeutics, Inc..